Abstract
Purpose :
To evaluate vitreoretinal interface disorders and macular changes in the fellow eyes of patients with lamellar macular hole (LMH).
Methods :
Patients were divided in three groups based on their optical coherence tomography (OCT) features of the main eye at baseline: group A (LMH), group B (mixed lesions) and group C (macular pseudohole (MPH) or epiretinal membrane foveoschisis (EMF)). History of retinal conditions including rhegmatogenous retinal detachment (RRD), retinal tear (RT), vitreo-macular surgery, and OCT features at baseline and last follow-up were recorded and compared between the three groups.
Results :
Ninety eights patients were enrolled in this study: 58 in the group A, 20 in the group B and 20 in the group C. At baseline, a significantly higher rate of RRD in fellow eyes was noted in group A (8/58, 14%) compared to the other groups (0/40, 0%), P = 0.020. Five out of 58 other eyes in group A (9%), 4/20 (20%) in group B and 0/20 (0%) in group C had a history of laser treated retinal tear (P = 0.080).
A significant higher rate of FTMH was found in fellow eyes of group A (11/58, 19%), compared to groups B (1/20, 5%) and C (1/20, 5%), P = 0.045. In the group A, three of 58 others patients (5%) showed a bilateral LMH, and one of 58 (2%) had a vitreomacular traction.
A epiretinal material, which had common OCT features than the proliferation described in LMH, was present in 28/58 fellow eyes in group A (48%), 5/20 fellow eyes in group B (20%) and 1/20 in group C (5%), P = 0.001.
Over the follow-up period, two fellow eyes in the group A developed a LMH and another one developed a FTMH.
Conclusions :
A high rate of macular and peripheral vitreoretinal diseases was noted in LMH’s fellow eyes. In addition, isolated epiretinal proliferation was detected in the macular area of a much higher number of fellow eyes in Group A versus groups B or C. This proliferation and the high rate of retinal pathologies seen on LMH’s fellow eyes suggest a potential bilateral intraretinal degenerative process in LMH.
This abstract was presented at the 2019 ARVO Imaging in the Eye Conference, held in Vancouver, Canada, April 26-27, 2019.